Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/o0, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12 \ \ o1/o1/o2, \ o1/o1/o3, \ o1$

| Name | of entity | | |
|-------|--|--------------------------------------|--|
| EVO | EVOLUTION MINING LIMITED (Evolution or Company) | | |
| L | | | |
| ABN | | | |
| 74 08 | 34 669 036 | | |
| We (| the entity) give ASX the following i | nformation. | |
| | t 1 - All issues nust complete the relevant sections (attach s | heets if there is not enough space). | |
| 1 | *Class of *securities issued or to be issued | Share Rights | |
| | | | |
| | | 97,788 | |

⁺ See chapter 19 for defined terms.

Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

The award of Share Rights to Non-Executive Directors (NEDs) are issued under the Non-Executive Director Equity Plan and was approved by shareholders at the Annual General Meeting on 24 November 2016.

Under the NED Equity Plan, NEDs are granted Share Rights as part of their remuneration, with the number of Share Rights calculated accordance with the following formula:

"Equity Amount" (\$) for the financial year/Value per Share Right

Where:

- "Equity Amount" is an amount determined by the Board, having regard to level of board and committee fees paid in cash and independent advice received. For FY2017, the Equity Amount is \$40,000 for each NED.
- the Value per Share Right = the volume weighted average market price of Evolution's ordinary shares traded on the ASX over the 5 trading day period up to and including 30 June each year. For FY2017, the VWAMP used to determine the number of share rights to be granted to each NED was \$2.4542.

Providing the NED remains a director of Evolution, Share Rights will vest and automatically exercise 12 months after the grant date.

Vested Share Rights will convert into ordinary shares on a one-for-one basis. Upon vesting and the transfer of shares to the relevant NED, the shares will be subject to disposal restrictions (Disposal Conditions) under the earlier of:

- the NED ceasing to be a director of Evolution; and
- 3 years from the date of grant of the share rights or such longer period nominated by the NED at the time of the offer (up to a maximum 15 years from the date of grant).

Generally, Share Rights will lapse if a NED ceases to be a Director of the Company.

Do the *securities rank equally No. Share Rights do not rank equally with existing 4 fully paid ordinary securities from the date of issue in all respects from the date of and do not participate in any dividend, distribution or allotment with an existing +class interest payment. of quoted *securities? Any fully paid ordinary share allotted on the If the additional securities do conversion of Share Rights will rank equally in all respects with existing issued fully paid ordinary not rank equally, please state: shares. the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution interest payment Issue price or consideration Nil 5 The Share Rights are issued under the Non-Purpose of the issue 6 Executive Director Equity Plan. (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i N/A 6b The date the security holder resolution under rule 7.1A was passed Number of *securities issued N/A 6с without security holder approval under rule 7.1 N/A Number of *securities issued 6d

under rule 7.1A

with security holder approval

⁺ See chapter 19 for defined terms.

| | 6e | Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | N/A | |
|---|----|--|-------------------------|---|
| (| 6f | Number of securities issued under an exception in rule 7.2 | N/A | |
| (| 6g | If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation. | N/A | |
| • | 6h | If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | N/A | |
| • | 6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements | N/A | |
| • | 7 | Dates of entering *securities into uncertificated holdings or despatch of certificates | 9 December 2016 | |
| : | 8 | Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable) | Number 1,679,732,397 | ⁺ Class Fully Paid Ordinary Shares |
| | | | | |

| 9 | Number | and | +class | of | all |
|---|--------------------------|---------|--------|------|-----|
| | +securitie | s not o | quoted | on A | SX |
| | (including | the | securi | ties | in |
| | section 2 if applicable) | | | | |
| | | | | | |

| Number | +Class |
|------------|--|
| 24,064,214 | Performance Rights |
| 3,750,000 | Performance Rights – subject to shareholder approval |
| 97,788 | Share Rights |

of a trust, distribution policy)
on the increased capital
(interests)

No change - All Shares participate equally

Part 2 - Bonus issue or pro rata issue

| 11 | Is security holder approval required? | |
|----|--|--|
| 12 | Is the issue renounceable or non-renounceable? | |
| 13 | Ratio in which the *securities will be offered | |
| 14 | ⁺ Class of ⁺ securities to which the offer relates | |
| 15 | ⁺ Record date to determine entitlements | |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | |
| 17 | Policy for deciding entitlements in relation to fractions | |
| 18 | Names of countries in which the entity has *security holders who will not be sent new issue documents | |
| | Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. | |
| | Cross reference, rule 7.7. | |
| 19 | Closing date for receipt of acceptances or renunciations | |
| | | |

⁺ See chapter 19 for defined terms.

| 20 | Names of any underwriters | |
|-----|---|---|
| 21 | Amount of any underwriting fee | |
| | or commission | |
| 22 | Names of any brokers to the issue | |
| | | |
| 23 | Fee or commission payable to the broker to the issue | |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders | |
| 25 | If the issue is contingent on | |
| 25 | *security holders' approval, the date of the meeting | |
| - (| Date antidoment and accordance | Г |
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled | |
| 257 | If the entity has issued entions | |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | |
| | 5 | |
| 28 | Date rights trading will begin (if applicable) | |
| | | |
| 29 | Date rights trading will end (if applicable) | |
| | ** 1 ± ° 1 11 11 | |
| 30 | How do *security holders sell their entitlements <i>in full</i> through a broker? | |
| | | |
| 31 | How do *security holders sell part of their entitlements through a broker and accept for | |

| | the balance? | | | |
|--------|---|--|--|--|
| 32 | How do *security holders dispose of their entitlements (except by sale through a broker)? | | | |
| 33 | ⁺ Despatch date | | | |
| | 3 - Quotation of securitied only complete this section if you are | | | |
| 34 | Type of securities (tick one) | | | |
| (a) | Securities described in Par | t 1 (in respect of the Fully Paid Ordinary Shares) | | |
| (b) | | Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible | | |
| | If the *securities are *equit | | | |
| 36 | | ty securities, a distribution schedule of the additional number of holders in the categories | | |
| 37 | A copy of any trust deed for | r the additional ⁺ securities | | |
| Entiti | ies that have ticked box 34(b) | | | |
| 38 | Number of securities for whic ⁺ quotation is sought | h N/A | | |
| | | | | |

⁺ See chapter 19 for defined terms.

| 39 | Class of *securities for which quotation is sought | N/A | |
|----|---|--------|--------|
| | | | |
| 40 | Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? | N/A | |
| | If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | | |
| 41 | Reason for request for quotation now | N/A | |
| | Example: In the case of restricted securities, end of restriction period | | |
| | (if issued upon conversion of another security, clearly identify that other security) | | |
| | | | |
| | | Number | +Class |
| 42 | Number and *class of all *securities quoted on ASX (including the securities in clause 38) | N/A | N/A |
| | | | |

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those *securities should not be granted *quotation.
- An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 9 December 2016

Company Secretary

Print name: Evan Elstein

⁺ See chapter 19 for defined terms.